what would be the right diagnosis for insurance to cover vsl # 3

• Periodical List
• HHS Author Manuscripts
• PMC3424311

Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2013 Sep i.

Published in terminal edited grade as:

PMCID: PMC3424311

NIHMSID: NIHMS395237

A Gastroenterologist's Guide to Probiotics

Abstract

The enteric microbiota contributes to gastrointestinal health and its disruption has been associated with many disease states. Some patients consume probiotic products in attempts to manipulate the intestinal microbiota for health do good. It is important for gastroenterologists to amend their understanding of the mechanisms of probiotics and the evidence that back up their apply in practice. Clinical trials have assessed the therapeutic effects of probiotics for several disorders, including antibiotic-or Clostridium difficile-associated diarrhea, irritable bowel syndrome, and the inflammatory bowel diseases. Although probiotic research is a rapidly evolving field, at that place are sufficient information to justify a trial of probiotics for treatment or prevention of some of these conditions. However, the chapters of probiotics to alter affliction symptoms is likely to be minor and varies among probiotic strains—not all probiotics are right for all diseases. The current review provides status-specific rationale for using probiotics every bit therapy and literature-based recommendations.

Keywords: Clostridium difficile, IBD, IBS, irritable bowel, clinical exercise, prove based do, Crohn'southward affliction and colitis, yogurt, pouchitis

INTRODUCTION

For over a hundred years information technology has been recognized that certain microorganisms may impart wellness benefits to the host when administered in adequate amounts. These microorganisms, termed probiotics, accept recently go a topic of significant focus in basic and clinical investigation. Relevant to the practice of gastroenterology, probiotics are usually used by patients with gastrointestinal complaints or diseases. Increasingly, probiotics are also beingness recommended past the clinicians who treat these conditions.¹

The goal of this review is to provide clinicians with an overview of the rationale and data which support or refute the function of probiotics for treating commonly encountered gastrointestinal disorders. The information provided is based on review of primary literature from randomized controlled trials (RCTs), meta-analyses, expert consensus panel recommendations and lodge-based practise recommendations. References are provided for more in depth reading and tables or figures summarize key information.

THE Human MICROBIOME AND PROBIOTIC MECHANISMS

To sympathise the function that probiotics may accept in influencing health, information technology is of import to take an appreciation of the roles of the normal abdominal microbiome (commensal microbiota). The homo gastrointestinal tract is host to over 500 bacterial species as well as a less well-described virome. These microbiota class a virtual bioreactor facilitating digestion, nutrient provision and the shaping of our immune system.² Our intestinal bacteria counterbalance upwards to 1 kg and bacterial cells outnumber human cells by 10:ane. The bacterial genome may outnumber the man genome by 100:1. Nutritional factors including several B vitamins, vitamin G, folate, and short chain fatty acids are produced by these bacteria. Up to 10% of anindividual's daily free energy needs can be derived from the byproducts of bacterial fermentation. Gastrointestinal microbiota are also critical for normal immune organization evolution.ⁱⁱⁱ The physiologic impact mediated by our resident microbes is substantial enough to take earned the label of "other organ" from some.⁴

Beyond contributing to or modifying the metabolic and nutritional functions of the commensal microbiota, probiotic bacteria have several putative mechanisms by which they may confer specific beneficial effects. General categories include modulation of immune or sensory-motor function, enhancement of mucosal barrier function and anti-pathogen effects (Figure 1).^5–7 Some of these mechanisms have been worked out in brute models and/or in vitro systems only.

Mechanisms of activeness for probiotics in the gastrointestinal tract

Soluble products secreted or shed by probiotics too mediate important physiologic benefits; thus feasible leaner are not necessarily required for all benefits.^{viii, 9} The mechanisms by which probiotics exert benefit varies by specific probiotic strain and likely depends on the clinical indication.^{10, eleven} Therefore, as with antibiotic prescribing, clinical utilise of probiotics should focus on matching the probiotic strain and dosage to the condition for which it has shown benefit in clinical trials. In the futurity, greater understanding of probiotic specific mechanisms could allow for precise selection of a detail probiotic strain to target a patient's specific pathogenic defect and clinical problem.

PROBIOTIC CONCEPTS FOR Practice

What makes a probiotic a probiotic?

Definitions of the terms probiotic, prebiotic and synbiotic are provided in Tabular array 1. This review focuses on probiotics, though some probiotics have been tested every bit part of a synbiotic product. Lactobacillus and bifidobacterium species are the most commonly used probiotics. Notwithstanding, one of the offset probiotics, which is still in use, is the not-pathogenic Escherichia coli Nissle 1917 (ECN). Most probiotics were initially cultured from humans and resemble known commensal gut bacteria. However, the commensal population they resemble typically represents merely a fraction of the total luminal bacteria. Saccharomyces boulardii is a probiotic yeast strain with the potential advantage of having resistance to most antibiotics.

Table 1

Definitions

Probiotics	Live microorganisms that confer a health benefit on the host when administered in adequate amounts
Prebiotic	Dietary substances that nurture specific changes in the composition and/or activity of the gastrointestinal microbiota (favoring benign bacteria), thus conferring benefit(southward) upon host health
Synbiotics	Products that contain both probiotics and prebiotics

According to current definitions, probiotics should survive both gastric acrid and bile to reach the small-scale intestine and colon where they exert their effects. Clinical and bones investigations on probiotics have used a multitude of probiotic species, both as single strains and multi-species products. Many of these probiotics are bachelor in a lyophilized (freeze-dried) pill form, though some are available in yogurt or as packets (sachets) which tin be mixed into non-carbonated drinks. Whether synergism or antagonism exists between probiotic species when offered together has non been examined in clinical studies, though both scenarios are theoretically possible. Though not exhaustive, Table 2 lists several of the more commonly available probiotic preparations which take shown benefit in human trials. Probiotics are considered dietary supplements; thus, they are not covered by medical insurance and their production is not regulated past the Food and Drug Administration. As such, product quality, purity and viability have been reported to be variable.¹² However, several clinically tested probiotic products with quality-controlled production are now marketed by reputable companies.

Table ii

Common probiotic products specifically tested for gastrointestinal disorders

Brand Name (Company)	Bacterial Species	Clinical Status	Effectiveness 15,16	Practice Guidelines 17–19	Bacteria Count/Dosing	Cost/Quantity
Activia (Dannon, White Plains, NY)	B. lactis DN-173 010, (plus yogurt starters L. bulgaricus, L. lactis and Streptococcus thermophilus)	IBS	C	1b**	4 oz/cup, 1–four QD	$10–18/24 count
Marshal (Proctor & Take chances, Cincinnati, OH)	Bifidobacterium infantis 35624	IBS	B	1b**	1 billion/ane QD	$29.99/28 count
BioGaia (Everidis Health Sciences, Saint Louis, MO)	Fifty. reuteri protectis SD2112 (ATCC 55730 or DSM 17928)	Infectious Diarrhea Treatment	A	1a*	100 one thousand thousand QD	$29.99
		IBS	C	1b*
Bio-Grand+ (Bio-Chiliad plus International inc., Laval, QC, Canada)	Fifty. acidophilus CL1285 and L. casei LBC80R	AAD Prevention	NS	1b**	50 billion/capsule	$29.99/15 count
		CDAD Prevention		1b**	BID
Culturelle (Valio, Helsinki, Finland/Amerifit Brands, Inc., Cromwell, CT)	L. rhamnosus GG (LGG) (LGG besides included in Danimals yogurt, Dannon)	AAD Prevention	A	AAP, 1b*,1b**	10 billion/ane QD	$xviii–25/xxx count
		Infectious Diarrhea Handling	A	AAP, 1a*, 2b**
		Infectious Diarrhea Prevention	B	1b*, 1b**
		CDAD Prevention	B/C
		CDAD Prevention of Recurrence	B/C
		Crohn'southward Disease	C
		IBS	B/C (children)	1a*,1b** +
Danactive (Dannon. White Plains, NY)	Lactobacillus casei DN-114001	AAD Prevention	A	1b**	3.1 oz/loving cup	$5.00/eight count
		Infectious Diarrhea Prevention		1b*	10 billion/loving cup
		CDAD Prevention		1b**
Florastor (Biocodex, Inc., Creswell, OR)	Saccharomyces Boulardii	AAD Prevention	A	AAP, 1a*, 1b**	250 mg/one BID	$19.99/20 count
		Infectious Diarrhea Treatment	A	1a*,1b**
		Infectious Diarrhea Prevention	B
		CDAD Prevention	B/C
		CDAD Prevention of Recurrence	B/C	1b**
		Crohns	C
Mutaflor (Ardeypharm, Herdecke, Germany)	E.coli Nissle 1917 (ECN)	UC Consecration	B		100 mg/capsule/BID	$62–$81/60
		UC Maintenance	A	1b**, BSG "A"		Canada#
VSL * iii (Sigma-Tau Pharmaceuticals, Inc., Towson, Doc)	Combination Probiotic Product (Streptococcus thermophilus, B. breve, B. longum, B infantis, 50. acidophilus, L. plantarum, Fifty. paracasei, Fifty. delbreuckii/bulgaricus	IBS	B/C		122.v billion/capsule	$86/30 Sachets
		UC Induction	B	1b**	450 billion/sachet	$52/60 count
		UC Maintenance	A		IBS: ½–1 sachet/day
		Pouchitis: Prevention and Maintaining Remission	A	1b**, BSG "B"	Pouchitis: two–4 sachets/day UC: 1–8 sachets/twenty-four hours

Does whatsoever yogurt work merely similar a probiotic?

Lactic acid producing leaner have been used for centuries in nutrient fermentation. Many yogurts contain live-active lactobacillus cultures and are considered functional nutrient products; however, nearly are not considered probiotics per se. This term is reserved for products with an adequate number of microorganisms at fourth dimension of consumption specifically shown to confer health benefits in controlled human trials. Yogurts fortified with an adequate number of viable bacteria shown to exert benefit in controlled trials are classified as probiotics. Given this data, and the knowledge that probiotic benefits appear species specific, expected clinical endpoints may not be achieved by generically recommending yogurt to patients in whom a purported probiotic benefit is desired. Information technology should be noted, yet, that yogurt consumption has other benefits including improved lactose tolerance and the provision of protein, vitamin D and calcium.

How long does 1 take to accept a probiotic?

As viable microorganisms, probiotics can survive in the human gut and affect microbes which colonize the gut. Probiotics are often detectable in the stool by culture or gene-based assays during periods of consumption. However, many probiotic strains practise not colonize the gut and are no longer recoverable in stool ane–four weeks after stopping consumption.^thirteen For instance, McNulty and colleagues recently evaluated a fermented milk product with probiotic strains matching the commercially bachelor Activia (Dannon, White Plains, NY). The investigators showed that the probiotic product did non modify the gut's overall bacterial composition, but instead altered gene expression patterns relevant to saccharide metabolism in the host's resident gut microbes.^xiv These changes in the human fecal "metatranscriptome" were transient, bars merely to the fourth dimension of the probiotic consumption. Thus, if sustained do good from a probiotic is desired, connected consumption is probable required.

Where can probiotics fit into a therapeutic algorithm?

Data for probiotic utilize in several GI disorders is reviewed in the post-obit section. For antibody associated diarrhea and viral gastroenteritis supporting data are strong and probiotics are amid the only treatment modalities available. However, the duration of symptoms in these weather is typically brusk regardless of probiotic use. In ulcerative colitis, pouchitis and irritable bowel syndrome adequate information exists for clinicians to consider recommending a therapeutic trial of specific probiotic strains or preparations in selected patients. In these weather condition probiotics are ordinarily administered as adjunctive therapy, rather than main or kickoff-line therapy. The decision to recommend probiotic therapy ultimately depends on the clinical scenario, patient interest and clinician preference. In hepatic encephalopathy, Crohn's disease and Clostridium difficile-associated diarrhea (CDAD), conventional medical therapies remain the gold standard. Practice relevant probiotic concepts are summarized in Table 3.

Tabular array three

Practical considerations relevant to probiotics in practice

• Common side effects of probiotics are typically transient only include gas and bloating.

• Different probiotic strains possess unique backdrop for benefiting host physiology

• One probiotic does not fit all GI illnesses; probiotic pick should be based on the clinical indication and take into consideration the strain and dosage used in clinical trials

• Symptomatic benefits offered by probiotics are likely to be modest; thus, probiotic therapies may best be used to supplement rather than replace conventional therapies

• Continuous consumption throughout the period of desired issue appears required for probiotics.

• Avoid probiotics in the critically sick and those with severe allowed compromise

PROBIOTIC THERAPY FOR GASTROINTESTINAL Conditions

Acute Onset Infectious Diarrhea

Several randomized controlled trials (RCTs) have evaluated the use of probiotics in acute infectious diarrhea. The data are largely from pediatric studies where both prevention and treatment were examined. Trials were conducted beyond the world with durations of upward to 1 year. In the pediatric population, rotavirus has been the nearly common cause of infectious diarrhea. Data suggests that the do good of probiotics in preventing astute infectious diarrhea is pocket-size.^{18, 21} Lactobacillus rhamnosus GG (LGG), Fifty. reuteri and Fifty. casei all have shown benefit, with an gauge NNT of 7 children to forestall 1 case of rotavirus in the child care middle setting.^22–24 With the currently bachelor rotavirus vaccine in consideration, the American University of Pediatrics states that probiotics for preventing astute infectious diarrhea are non universally endorsed, but acknowledges that they may accept a role in special circumstances.¹⁸ According to the United states Center for Disease Control, data is not sufficient to support the utilize of probiotics such equally LGG to forbid traveler'due south diarrhea of bacterial origin.

The data supporting handling of acute infectious diarrhea with probiotics are stronger. LGG is the well-nigh effective probiotic reported on to date, reducing both severity and duration of diarrhea past ~i day.^{25, 26} The American Academy of Pediatrics supports the recommendation of LGG early in the course of acute infectious diarrhea to reduce symptom duration.¹⁸

Antibiotic Associated Diarrhea

Antibiotic use is common in children, and diarrhea develops in ~xx% of those taking antibiotics. Prevention of non-C.difficile-related antibiotic associated diarrhea (AAD) with probiotics has been assessed in RCTs. A 2011 Cochrane Review evaluating >3400 patients from 16 studies concluded that the overall evidence suggests a protective effect of probiotics in preventing AAD.²⁷ Studies using LGG and Southward. boulardii produced the nearly convincing results.²⁸ The NNT to foreclose one example of AAD was ~7 in the Cochrane Review. The American Academy of Pediatrics supports the recommendation of probiotics for prevention of, simply not treatment of, AAD.^eighteen

In the adult population probiotics also appear effective in limiting AAD. A meta-analysis evaluating studies on various probiotics and antibiotic regimens published between 1977–2005 plant that both LGG and S. Boulardii offered a reduction in risk of AAD development (combined RR 0.31 and 0.37 respectively).²⁹ Two recent placebo-controlled RCTs evaluated combination probiotic products for the prevention of antibody associated diarrhea as their primary endpoint. Hickson et al used the probiotic mixture currently marketed as DanActive (Dannon, White Plains, NY) in the United States and institute that it significantly reduced AAD (12% vs. 34%) in an older cohort of hospitalized patients.³⁰ A second study evaluated a combination probiotic containing both L. casei and 50. acidophilus (Bio-K+, Bio-Yard Plus International, Quebec, Canada) in 255 patients. Patients given the higher dose of probiotic concurrent with antibiotics (and for 5 days afterward) had fewer occurrences of AAD (15.v vs. 44.1%).³¹ As a secondary endpoint, both of these studies also showed a reduction in development of C. difficile-associated diarrhea (discussed beneath).

Clostridium Difficile Associated Diarrhea

C.difficile-associated diarrhea (CDAD) is a common nosocomial and community-based medical status. While typically linked to antibody induced disturbance of the intestinal microbiota, CDAD is now increasingly identified in patients without recent antibiotic exposure.³² Antibiotic therapy with metronidazole, oral vancomycin and now fidaxomicin makeup the electric current treatment prototype.³³ Recurrence of CDAD remains a clinical problem. In 1994 a trial reported that South. boulardii (500mg bid) offered for 4 weeks afterwards antibiotic therapy reduced overall CDAD recurrence rates.³⁴ All the same, the finding was only significant for those with a history of recurrent CDAD. A follow upward study, designed to be confirmatory, did non find Southward. boulardii to significantly reduce CDAD recurrence after standard therapy.³⁵ Though a favorable trend was found in patients treated with high-dose vancomycin (2 thou/day) in the latter study, the clinical significance of this is less articulate. Lactobacillus probiotics have been tested as single species and as combination probiotic products for preventing CDAD recurrence. While some results take been promising, almost studies are underpowered, have methodological flaws, or have not been reproduced.³⁶

Probiotic-based chief prevention still may be an approach to the current scourge of C. difficile. The two recent probiotic trials discussed higher up in the AAD section advise that this may be feasible. The Hickson study reported that DanActive supplementation in older hospitalized adults reduced AAD, merely also CDAD (0% vs. 17% placebo).³⁰ The study evaluating the combination probiotic Bio-Yard+ also showed a reduction in CDAD in the treated cohort (1.2% vs. 23.8% placebo).³¹ The high incidence rate of C.difficile positivity in the placebo groups (17% and 23.8%) is a criticism for both of these studies. All the same, if confirmatory studies bear witness like results, these intriguing findings may lead to a paradigm shift in managing older adults requiring antibiotic therapy.

While controversy exists, electric current society guidelines and expert opinion panels country that existing data are non sufficient to justify recommending bachelor probiotics for preventing principal or recurrent CDAD.^{15, 36, 37}

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is characterized by symptoms of abdominal pain and altered bowel habits which occur over at least 3 months. This mutual disorder is managed with varying clinical styles as no dominant therapeutic strategy has emerged.³⁸ The pathophysiology of IBS remains unknown, but several lines of evidence link symptomatic expression of this disorder with the intestinal microbiota. IBS patients may have subtle differences in their luminal and mucosal-associated intestinal microbiota compared to controls.^{39, 40} New onset IBS symptoms can develop in upwards to one-third of individuals afterward recovery from a self-limited episode of infectious gastroenteritis.^{41, 42} Small-bowel bacterial overgrowth has been reported in a proportion of IBS patients, and antibiotics offer relief of IBS symptoms in some individuals.^{43, 44} And then, while controversy exists, bacteria probable contribute to at least some symptoms of IBS.⁴⁵

Several clinical trials have investigated the potential for probiotics as therapy in IBS. These trials are the subject of several single topic reviews.^{sixteen, 46, 47} Systematic summarization of these results is complicated by the inclusion of several probiotic strains/species, single or combination preparations, dosing regimens and unique study designs. Several studies included endpoints which were not clinically applicable or demonstrated improvement over baseline, but not compared to placebo.^sixteen Most studies were short term merely; data on long-term efficacy are still defective.

A meta-analysis of 3 RCTs suggests that LGG moderately improves pain symptoms in children with IBS (NNT=4).⁴⁸ Traditional IBS handling endpoints have not been adequately met in studies of other single strain lactobacillus species in adults.¹⁶ A Bifidobacterium infantis strain (B.infantis 35624, Align, Proctor and Gamble, Cincinnati, OH) was evaluated in ii clinical trials. One report found significant reductions in pain, bloating, bowel movement difficulty and composite symptom score versus placebo and a lactobacillus species.⁴⁹ In a larger follow-up written report, reduction in pain and global relief of IBS symptoms were significantly greater in the B.infantis treated group compared to placebo.^l

General recommendations from the American Higher of Gastroenterology as well as expert consensus panels from both the United States and in Europe are similar.^{15, 17, 38} There is reasonable rationale for why probiotics may work equally treatment for IBS. There are at least some positive controlled studies showing that probiotic supplementation reduces IBS symptoms in some patients. The prove of benefit is not sufficiently potent to support the general recommendation of probiotics for IBS; however, the benefit appears greatest for bifidobacteria species and certain combinations of probiotics which include bifidobacteria species rather than single species lactobacillus probiotics.

With probiotics, patients might experience a global improvement in symptomatology rather than specific improvement in bowel function. Since handling options for IBS remain limited in both number and efficacy, a therapeutic trial of probiotics is reasonable for patients interested in this approach.

Inflammatory Bowel Diseases

Evidence points to the intestinal microbiome being a key actor in the evolution and perpetuation of the inflammatory bowel diseases.⁵¹ Defects in the innate allowed response to commensal abdominal bacteria resulting in an exaggerated adaptive immune response to these organisms are implicated in the pathogenesis of Crohn's illness (CD).⁵² Several key CD risk genes have functions related to bacterial killing, and antibiotics have therapeutic efficacy in CD and pouchitis.^{53, 54} Compared to CD, a cardinal office for gut bacteria is less strongly implicated in the pathogenesis of ulcerative colitis.⁵⁵ However, the testify supporting probiotics in patient management is better for UC and pouchitis than for CD.

Several limitations exist with trials which have evaluated probiotic therapy in the inflammatory bowel diseases. These include small cohort sizes, use of different probiotic doses and strains, varied treatment durations and differences in concurrent conventional treatments. Regardless, patients with IBD often take or consider taking probiotics and appreciate their clinician having knowledge of the topic.

Crohn'due south Disease

Probiotic use in the management of Crohn's disease is not supported by currently available RCT data. Trials take found LGG and other lactobacilli not superior toplacebo every bit an additive to standard care for inducing or maintaining remission in CD or for preventing mail operative relapse.^56–58 In that location is also no solid data to support the utilize of ECN or S. boulardii in CD.⁵⁹

Ulcerative Colitis

Several published RCTs accept shown benefit of probiotics in the management of ulcerative colitis (UC). These studies have examined induction of remission and maintenance of remission typically by comparing the probiotic to oral mesalamine or adding the probiotic to standard therapy. ECN at 200 mg/twenty-four hours was similar in efficacy to 1500 mg of mesalamine for maintaining UC in remission.⁶⁰

High dose VSL#3 (3.6 trillion cfu/mean solar day) has shown therapeutic efficacy in two RCTs evaluating patients with balmy-to-moderately active UC. When offered to UC patients having a flare while on a 5-ASA or an immunomodulator, the probiotic cohort demonstrated improved symptom-based disease activeness indices and rectal bleeding, but not endoscopic scores, compared to the placebo group.⁶¹ A report conducted in Republic of india included 144 adults with relapsing UC and showed the VSL#3 group to have significantly higher remission rates (42.ix% vs. fifteen.9%) and endoscopic healing (32% vs. 14.7%).⁶² Most patients in both groups remained on a stable dose of mesalamine therapy. A high dropout-rate in both groups (29% VSL3, 59% placebo) was a limitation of the latter written report. VSL#3 was also shown to amend rates of induction and maintenance of remission in children with UC (north=29 total).⁶³ Recent Cochrane reviews conclude that there is insufficient data to demonstrate that probiotics have efficacy in maintaining remission in UC; all the same, they have not recently addressed induction of remission in UC.⁶⁴ Single strain lactobacillus and bifidobacterium (infantis 35624, Align) probiotics did not show efficacy for maintaining UC remission in clinical trials.^{65, 66}

In summary, the overall bear witness suggests that ECN and VSL#3 have modest efficacy, similar to and perhaps complementary to mesalamine, in inducing and maintaining remission for balmy-to-moderately active UC.

Pouchitis

Chronic or recurrent pouchitis is an important complication occurring in ~x–20% of UC patients afterwards ileal anal pouch formation surgery. VSL#iii was shown beneficial in prophylaxis against pouchitis onset afterward surgical have-down ⁶⁷ and in maintaining clinical remission after antibody induction.^{68, 69} These trials were conducted in Europe and included ~20 patients per group. A practice based report from the Cleveland Clinic found only 19% (6 of 31) of patients who were started on VSL#3 after handling with antibiotics to yet exist taking the probiotic at 8 months.⁷⁰ A single study from the Netherlands constitute that compared to a historical cohort, patients taking LGG had a delayed onset of pouchitis at 3 years (7% vs. 29%).⁷¹

Clinical adept-generated guidelines concur that probiotics (VSL#3) can be effective for preventing recurrence of pouchitis.^{15, 72, 73}

Complications of Chronic Liver Illness/Hepatic Encephalopathy

Luminal microbiota play an of import part in the pathogenesis of both spontaneous bacterial peritonitis and hepatic encephalopathy. Ammonia produced by gut bacteria is believed to play a key role in hepatic encephalopathy. Antibiotics are employed in clinical practice to reduce severity or frequency of both these chronic liver illness complications. Lactulose, a mainstay of therapy, is a prebiotic for lactobacilli which can limit bacterial ureases.

The role for probiotics in these disorders is an area of ongoing investigation.⁷⁴ Handling of hepatic encephalopathy with lactobacillus acidophilus was studied as early as 1965.⁷⁵ More recently, Liu and colleagues offered a probiotic and prebiotic mixture to 97 patients with minimal hepatic encephalopathy and observed a reduction in ammonia levels and improvement in encephalopathy.⁷⁶ Another group establish that a yogurt-based probiotic supplement significantly improved quantitative measurements of minimal hepatic encephalopathy in nonalcoholic cirrhotics.⁷⁷ The latter group is now completing a more than comprehensive trial using the probiotic LGG in a similar patient cohort.⁷⁸

Society guidelines and expert consensus panels do non currently support a recommendation of probiotic use for any chronic liver disease associated condition.

SAFETY OF PROBIOTICS

For nearly populations, probiotic consumption is considered safe and complications rare. A review on the rubber of probiotics by Snydman points out that although example reports of bacteremia and endocarditis (LGG) as well as cases of fungemia (S. boulardii) exist, epidemiologic evidence suggests that there is no overall increase in population-chance based on usage data.⁷⁹ This position is substantiated past a recent The states regime commissioned review console report.^eighty As a caveat still, a high profile multicenter placebo controlled Dutch RCT examining probiotic supplementation in severe acute pancreatitis plant a higher incidence of mesenteric ischemia and expiry in the treatment group.⁸¹ This is the only trial to date to infer such a relationship, but supports the concept that probiotics should be avoided in critically ill patients. Indwelling central vein catheters and perhaps cardiac valvular illness may be relative contraindications.⁸²

WHAT LIES Ahead FOR PROBIOTICS IN DIGESTIVE DISEASES

Inspired investigators and technical advances in genomics are facilitating in-depth scientific investigation of the human microbiome and the functional capacities of probiotics. These advances are sure to bring paradigmatic changes to our central understanding of how microbiota influence health and how they tin be manipulated to gainsay illness and improve quality of life. Future indications and therapeutic directions for probiotics may include conditions as diverse as mood disorders, obesity, autism and diabetes. Recent clinical trials and translational studies propose that lactobacillus probiotics may offer epithelial cytoprotection to limit symptoms of radiation enteritis, a dose limiting side consequence for patients receiving abdominal radiotherapy for malignancy.^{8, 83, 84} Promise is held for confirmative testing of helminth-based therapy and "turbo-probiotics" designed to secrete human cytokines. Factor based bacterial profiling studies from disease afflicted humans have identified what may be novel "probiotics" such as Faecalibacterium prausnitizii and Clostridium species 4 and XIVa. Finally, the identification, purification and repackaging of probiotic-derived soluble factors possessing proven capacity to alter biologic function may allow us to harness the ability of probiotics while averting the potential risks associated with live leaner. Some suggest that as these advances progress to the clinic nosotros will shift from the term probiotic into the new world of pharmabiotics.⁸⁵

CONCLUSIONS

Evidence supports a role for because the recommendation of conventional probiotics for some clinical conditions. Probiotic strain choice should focus on quality tested products with clinically demonstrated benefit for the given disorder. Patients and physicians should expect pocket-size effects and consider using probiotics every bit a supplement to, rather than a replacement for, conventional therapy. Though challenges be, ongoing investigations offering groovy promise for the future. Perhaps one day clinicians will have the opportunity to apply directed option of a probiotic or probiotic derived production to specifically accost a patient'south unique disease causing physiologic or genetic defect.

Acknowledgments

Grant Support: MAC has funding from NIH grant DK089016

Piece of work partially supported by NIH grant DK089016. I thank my colleagues at Washington University for their critical assessment of this review and for the knowledge shared by participants at the 2011 FASEB conference on Probiotics.

Abbreviations

CD	Crohn's affliction
UC	ulcerative colitis
IBS	irritable bowel syndrome
RCT	randomized controlled trial
AAD	antibiotic associated diarrhea
CDAD	Clostridium difficile-associated diarrhea
ECN	E.coli Nissle 1917
LGG	Lactobacillus rhamnosus GG

Footnotes

Writer Interest: MAC drafted the manuscript in entirety

Disclosures: MAC received support for laboratory inquiry from VSL Pharmaceuticals, Inc.

Publisher'due south Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. Every bit a service to our customers we are providing this early on version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its terminal citable form. Please notation that during the production process errors may be discovered which could affect the content, and all legal disclaimers that employ to the journal pertain.

References

1. Williams Doctor, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. J Clin Gastroenterol. 2010;44:631–636. [PMC gratuitous article] [PubMed] [Google Scholar]

2. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut microbiome and the immune system. Nature. 2011;474:327–336. [PMC free article] [PubMed] [Google Scholar]

iii. Macpherson AJ, Harris NL. Interactions between commensal abdominal bacteria and the immune organisation. Nat Rev Immunol. 2004;iv:478–485. [PubMed] [Google Scholar]

4. Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and illness. Physiol Rev. 2010;xc:859–904. [PubMed] [Google Scholar]

five. Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: contempo advances. Inflamm Bowel Dis. 2009;15:300–310. [PubMed] [Google Scholar]

six. Madsen KL. Interactions between microbes and the gut epithelium. J Clin Gastroenterol. 2011;45(Suppl):S111–114. [PubMed] [Google Scholar]

7. Rousseaux C, Thuru Ten, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;xiii:35–37. [PubMed] [Google Scholar]

eight. Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent mode. Gut. 2011 Epub ahead of print. [PMC gratis article] [PubMed] [Google Scholar]

nine. Yan F, Cao H, Cover TL, et al. Colon-specific commitment of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest. 2011;121:2242–2253. [PMC free article] [PubMed] [Google Scholar]

10. Shanahan F. Probiotics in perspective. Gastroenterology. 2010;139:1808–1812. [PubMed] [Google Scholar]

11. Mileti East, Matteoli K, Iliev ID, et al. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex civilisation systems: prediction for in vivo efficacy. PLoS 1. 2009;iv:e7056. [PMC costless article] [PubMed] [Google Scholar]

12. Berman S, Spicer D. Safety and Reliability of Lactobacillus Supplements in Seattle, Washington. The Internet Periodical of Culling Medicine. 2003:1. [Google Scholar]

13. Sanders ME. Bear on of probiotics on colonizing microbiota of the gut. J Clin Gastroenterol. 2011;45(Suppl):S115–119. [PubMed] [Google Scholar]

14. McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med. 2011;3:106ra106. [PMC complimentary commodity] [PubMed] [Google Scholar]

15. Floch MH, Walker WA, Madsen 1000, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol. 2011;45(Suppl):S168–171. [PubMed] [Google Scholar]

sixteen. Ringel Y, Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2011;45(Suppl):S145–148. [PubMed] [Google Scholar]

18. Thomas DW, Greer FR. Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–1231. [PubMed] [Google Scholar]

nineteen. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607. [PubMed] [Google Scholar]

20. Heart for Evidence Based Medicine Levels of Evidence. 2009 www.cebm.cyberspace. Bachelor at: www.cebm.net.

21. Guandalini Southward. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–153. [PubMed] [Google Scholar]

22. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child intendance centers: comparison of two probiotic agents. Pediatrics. 2005;115:5–9. [PubMed] [Google Scholar]

23. Pedone CA, Arnaud CC, Postaire ER, et al. Multicentric study of the effect of milk fermented past Lactobacillus casei on the incidence of diarrhoea. Int J Clin Pract. 2000;54:568–571. [PubMed] [Google Scholar]

24. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138:361–365. [PubMed] [Google Scholar]

25. Szymanski H, Pejcz J, Jawien M, et al. Treatment of acute infectious diarrhoea in infants and children with a mixture of iii Lactobacillus rhamnosus strains--a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;23:247–253. [PubMed] [Google Scholar]

26. Allen SJ, Martinez EG, Gregorio GV, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010:CD003048. [PMC gratuitous article] [PubMed] [Google Scholar]

27. Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;xi:CD004827. [PubMed] [Google Scholar]

28. Szajewska H, Ruszczynski Grand, Radzikowski A. Probiotics in the prevention of antibody-associated diarrhea in children: a meta-assay of randomized controlled trials. J Pediatr. 2006;149:367–372. [PubMed] [Google Scholar]

29. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812–822. [PubMed] [Google Scholar]

30. Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double bullheaded placebo controlled trial. BMJ. 2007;335:80. [PMC free article] [PubMed] [Google Scholar]

31. Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105:1636–1641. [PubMed] [Google Scholar]

32. Kelly CP, LaMont JT. Clostridium difficile--more than hard than ever. Northward Engl J Med. 2008;359:1932–1940. [PubMed] [Google Scholar]

33. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, take a chance factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28:1–9. [PubMed] [Google Scholar]

34. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile affliction. JAMA. 1994;271:1913–1918. [PubMed] [Google Scholar]

35. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a meliorate treatment for recurrent Clostridium difficile disease: apply of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017. [PubMed] [Google Scholar]

36. Na 10, Kelly C. Probiotics in clostridium difficile Infection. J Clin Gastroenterol. 2011;45(Suppl):S154–158. [PMC free article] [PubMed] [Google Scholar]

37. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA) Infect Command Hosp Epidemiol. 2010;31:431–455. [PubMed] [Google Scholar]

38. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl 1):S1–35. [PubMed] [Google Scholar]

39. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301:G799–807. [PMC free commodity] [PubMed] [Google Scholar]

40. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24–33. [PubMed] [Google Scholar]

41. Marshall JK, Thabane M, Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome afterward a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131:445–450. quiz 660. [PubMed] [Google Scholar]

42. Spiller R, Garsed Grand. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136:1979–1988. [PubMed] [Google Scholar]

43. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-assay. Clin Gastroenterol Hepatol. 2009;seven:1279–1286. [PubMed] [Google Scholar]

44. Pimentel Yard, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. [PubMed] [Google Scholar]

45. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol. 2011;9:461–469. quiz e459. [PubMed] [Google Scholar]

46. Moayyedi P, Ford Air-conditioning, Talley NJ, et al. The efficacy of probiotics in the handling of irritable bowel syndrome: a systematic review. Gut. 2010;59:325–332. [PubMed] [Google Scholar]

47. Brenner DM, Moeller MJ, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009;104:1033–1049. quiz 1050. [PubMed] [Google Scholar]

48. Horvath A, Dziechciarz P, Szajewska H. Meta-assay: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–1310. [PubMed] [Google Scholar]

49. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and human relationship to cytokine profiles. Gastroenterology. 2005;128:541–551. [PubMed] [Google Scholar]

50. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101:1581–1590. [PubMed] [Google Scholar]

52. Sartor RB. Genetics and ecology interactions shape the abdominal microbiome to promote inflammatory bowel affliction versus mucosal homeostasis. Gastroenterology. 2010;139:1816–1819. [PubMed] [Google Scholar]

53. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317. [PMC gratis article] [PubMed] [Google Scholar]

54. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620–1633. [PubMed] [Google Scholar]

55. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725. [PubMed] [Google Scholar]

56. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn'southward illness. BMC Gastroenterol. 2004;4:5. [PMC free article] [PubMed] [Google Scholar]

57. Bousvaros A, Guandalini South, Baldassano RN, et al. A randomized, double-bullheaded trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn'south disease. Inflamm Bowel Dis. 2005;xi:833–839. [PubMed] [Google Scholar]

58. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405–409. [PMC complimentary commodity] [PubMed] [Google Scholar]

59. Meijer BJ, Dieleman LA. Probiotics in the handling of human being inflammatory bowel diseases: update 2011. J Clin Gastroenterol. 2011;45(Suppl):S139–144. [PubMed] [Google Scholar]

60. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as constructive every bit with standard mesalazine. Gut. 2004;53:1617–1623. [PMC free commodity] [PubMed] [Google Scholar]

61. Tursi A, Brandimarte M, Papa A, et al. Handling of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-bullheaded, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105:2218–2227. [PMC free commodity] [PubMed] [Google Scholar]

62. Sood A, Midha V, Makharia GK, et al. The probiotic grooming, VSL#3 induces remission in patients with balmy-to-moderately agile ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–1209. 1209, e1201. [PubMed] [Google Scholar]

63. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#three) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–443. [PubMed] [Google Scholar]

64. Naidoo Grand, Gordon K, Fagbemi AO, et al. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2011;12:CD007443. [PubMed] [Google Scholar]

65. Fujimori Southward, Gudis K, Mitsui Thou, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic handling to improve the quality of life in patients with ulcerative colitis. Nutrition. 2009;25:520–525. [PubMed] [Google Scholar]

66. Shanahan F, Guaraner F, von Wright A, et al. A one year, double-blind, placebo controlled trial of a Lactobacillus or a Bidfidobacterium probiotic for maintenance of steroid-induced remission of ulcerative colitis. Gastroenterology. 2006;130:A-44, 249. [Google Scholar]

67. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209. [PubMed] [Google Scholar]

68. Mimura T, Rizzello F, Helwig U, et al. Once daily loftier dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114. [PMC free article] [PubMed] [Google Scholar]

69. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy equally maintenance treatment in patients with chronic pouchitis: a double-bullheaded, placebo-controlled trial. Gastroenterology. 2000;119:305–309. [PubMed] [Google Scholar]

70. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721–728. [PubMed] [Google Scholar]

71. Gosselink MP, Schouten WR, van Lieshout LM, et al. Filibuster of the beginning onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47:876–884. [PubMed] [Google Scholar]

72. Pardi DS, D'Haens M, Shen B, et al. Clinical guidelines for the direction of pouchitis. Inflamm Bowel Dis. 2009;15:1424–1431. [PubMed] [Google Scholar]

73. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. :CD001176. [PubMed] [Google Scholar]

74. Lata J, Jurankova J, Kopacova M, et al. Probiotics in hepatology. World J Gastroenterol. 17:2890–2896. [PMC gratis article] [PubMed] [Google Scholar]

75. Macbeth WA, Kass EH, McDermott WV., Jr Handling of Hepatic Encephalopathy by Alteration of Abdominal Flora with Lactobacillus Acidophilus. Lancet. 1965;1:399–403. [PubMed] [Google Scholar]

76. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: issue on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441–1449. [PubMed] [Google Scholar]

77. Bajaj JS, Saeian Grand, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol. 2008;103:1707–1715. [PubMed] [Google Scholar]

79. Snydman DR. The safety of probiotics. Clin Infect Dis. 2008;46(Suppl 2):S104–111. discussion S144–151. [PubMed] [Google Scholar]

80. Hempel S, Newberry S, Ruelaz A, et al. Services USDoHaH. Safety of Probiotics to Reduce Chance and Preclude or Care for Disease. 2011. [PMC free article] [PubMed] [Google Scholar]

81. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe astute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371:651–659. [PubMed] [Google Scholar]

82. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83:1256–1264. quiz 1446–1257. [PubMed] [Google Scholar]

83. Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci. 2009;1165:190–194. [PMC gratis article] [PubMed] [Google Scholar]

84. Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol. 2010;26:88–94. [PMC free article] [PubMed] [Google Scholar]

85. Shanahan F, Collins SM. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders, from rationale to reality. Gastroenterol Clin North Am. 2010;39:721–726. [PubMed] [Google Scholar]

butleroicieffive.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424311/

Share this post